Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

被引：69
|
作者：
Cornberg M. [1 ]
Wedemeyer H. [1 ]
Manns M.P. [1 ]
机构：
[1] Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Carl-Neuberg-Strasse 1
来源：
Current Gastroenterology Reports | 2002年 / 4卷 / 1期
关键词：
Sustained Virologic Response; Sustained Virologic Response Rate; Million Unit; Sustained Response Rate; International Hepatitis Interventional Therapy Group;
D O I：
10.1007/s11894-002-0034-y
中图分类号：
学科分类号：
摘要：
Treatment with interferon alfa combined with ribavirin is successful in approximately 40% to 45% of patients with chronic hepatitis C viral infection (HCV). However, response rates are disappointing in patients who are difficult to treat, such as those infected with HCV genotype 1, high viral load, or advanced liver fibrosis. In addition, low tolerability and significant side effects of therapy frequently lead to dose reduction and treatment discontinuation, decreasing response rates further. Thus, investigation of new treatment options and innovations for chronic HCV infection are vital. This review describes recent advances in the treatment of HCV infection with PEGylated interferon (interferon modified with polyethylene glycol [PEG] ) combined with ribavirin.
引用
收藏
页码：23 / 30
页数：7
相关论文
共 50 条
  • [21] Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
    Cho, Hyun Chin
    Gwak, Geum-Youn
    Paik, Yong Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Yoo, Byung Chul
    Paik, Seung Woon
    [J]. GUT AND LIVER, 2013, 7 (05) : 585 - 593
  • [22] Pegylated interferon alfa and ribavirin for children with chronic hepatitis C
    Rosen, Irit
    Kori, Michal
    Adiv, Orly Eshach
    Yerushalmi, Baruch
    Zion, Nataly
    Shaoul, Ron
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (07) : 1098 - 1103
  • [23] Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C
    Kowala-Piaskowska, Arleta
    Mozer-Lisewska, Iwona
    Figlerowicz, Magdalena
    Sluzewski, Wojciech
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (10) : 1095 - 1103
  • [24] Treatment response of chronic hepatitis C virus infection with pegylated-interferon and ribavirin
    Humphris, J. L.
    Ngu, M. C.
    Lee, A. U.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A331 - A331
  • [25] Hepatitis C virus (HCV) core antigen kinetics during treatment of chronic hepatitis C with interferon alpha and/or ribavirin.
    Dahari, H
    Hezode, C
    Bouvier-Alias, M
    Dhumeaux, D
    Neumann, AU
    Pawlotsky, JM
    [J]. HEPATOLOGY, 2001, 34 (04) : 217A - 217A
  • [26] Pegylated Interferon Alpha-2a and Ribavirin in the Treatment of Children with Chronic Hepatitis C
    Pawlowska, Malgorzata
    Halota, Waldemar
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : A839 - A839
  • [27] Outcome of Treatment With Pegylated Interferon and Ribavirin in Heart Transplant Recipients With Chronic Hepatitis C
    Durante-Mangoni, E.
    Ragone, E.
    Pinto, D.
    Iossa, D.
    Covino, F. E.
    Maiello, C.
    Utili, R.
    [J]. TRANSPLANTATION PROCEEDINGS, 2011, 43 (01) : 299 - 303
  • [28] Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
    Rodriguez-Lojo, R.
    Almagro, M.
    Barja, J. M.
    Pineyro, F.
    Perez-Varela, L.
    Del Pozo, J.
    Yebra-Pimentel, M. T.
    Fonseca, E.
    [J]. DERMATOLOGY RESEARCH AND PRACTICE, 2010, 2010
  • [29] PEGYLATED INTERFERON ALPHA PLUS RIBAVIRIN TREATMENT OF CHRONIC HEPATITIS C IN PSORIATIC PATIENTS
    Tomasiewicz, Krzysztof
    Modrzewska, Romana
    [J]. HEPATOLOGY, 2008, 48 (04) : 907A - 907A
  • [30] Psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic Hepatitis C
    Kaabi, W.
    Youssef, S.
    Litaiem, N.
    El Khalifa, J.
    Jaber, K.
    Dhaoui, M. R.
    Doss, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 73 - 73
12345